MARKET

CORT

CORT

Corcept
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.41
-0.10
-0.49%
After Hours: 20.41 0 0.00% 16:44 09/20 EDT
OPEN
20.38
PREV CLOSE
20.51
HIGH
20.59
LOW
20.22
VOLUME
420.88K
TURNOVER
--
52 WEEK HIGH
31.18
52 WEEK LOW
16.42
MARKET CAP
2.37B
P/E (TTM)
26.54
1D
5D
1M
3M
1Y
5Y
Corcept Therapeutics' Relacorilant Combo Therapy Shows Clinical Benefit In Ovarian Cancer
Benzinga · 3d ago
Corcept Therapeutics Says Results Presented At ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant In Patients With Recurrent Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of
Benzinga · 3d ago
Chief Business Officer Of Corcept Therapeutics Makes $1.13 Million Sale
Gary Charles Robb, Chief Business Officer at Corcept Therapeutics (NASDAQ:CORT), made a large insider sell on September 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed t...
Benzinga · 4d ago
Insider Sell: Corcept Therapeutics
MT Newswires · 4d ago
Corcept Announces Presentation Of Results From Randomized Controlled Phase 2 Trial Of Relacorilant In Patients With Recurrent Platinum-Resistant Ovarian Cancer At ESMO 2021
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of
Benzinga · 09/09 20:21
Corcept Announces Presentation of Positive Results From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients With Recurrent Platinum-Resistant Ovarian Cancer at ESMO 2021
Data from Corcept’s 178-patient, randomized, controlled, Phase 2 trial to be featured in a proffered paper oral presentation at the upcoming ESMO conference on September 17, 2021Results show benefit experienced by women with recurrent platinum-resistant ov...
GlobeNewswire · 09/09 20:05
Corcept Therapeutics Granted U.S. Patent #11,103,514 'Treatment of muscular dystrophy'
View patent here
Benzinga · 08/31 11:48
BRIEF-William Guyer To Join Corcept As Chief Development Officer
reuters.com · 08/12 21:39
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CORT. Analyze the recent business situations of Corcept through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CORT stock price target is 25.25 with a high estimate of 35.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 302
Institutional Holdings: 102.58M
% Owned: 88.49%
Shares Outstanding: 115.93M
TypeInstitutionsShares
Increased
69
3.35M
New
16
218.60K
Decreased
74
4.03M
Sold Out
27
663.95K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.35%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Non-Executive Chairman/Independent Director
James Wilson
President/Chief Executive Officer/Co-Founder/Director
Joseph Belanoff
Chief Financial Officer/Treasurer
Atabak Mokari
Chief Accounting Officer
Joseph Lyon
Chief Scientific Officer
Hazel Hunt
Other
William Guyer
Other
Sean Maduck
Secretary
Gary Robb
Director
Joshua Murray
Independent Director
Gregg Alton
Independent Director
George Baker
Independent Director
Gillian Cannon
Independent Director
David Mahoney
Independent Director
Kimberly Park
Independent Director
Daniel Swisher
No Data
About CORT
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

Webull offers kinds of Corcept Therapeutics Incorporated stock information, including NASDAQ:CORT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CORT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CORT stock methods without spending real money on the virtual paper trading platform.